Preprint · OA
via OpenAlex
Gut dysbiosis and hypertension: is it cause or effect?
Katherine Loree Cook, Mark C. Chappell
Journal of Hypertension · 2021 · ▲ 12 citations
Epigenetic alterations
Dysbiosis
Chronic inflammation
Microbiome / FMT
Rat
Human
Mouse
Preclinical / animal
Abstract
The worldwide incidence of hypertension is at pandemic proportions with an estimated one in six adults exhibiting a sustained elevation in blood pressure [1]. Hypertension remains the leading risk factor for cardiovascular disease (CVD) in both men and women; however, the underlying mechanisms of the disease remain obscure [1]. The current treatment approaches for hypertension constitute pharmacological regimens targeting the renin--angiotensin--aldosterone system (RAAS) -- angiotensin converting enzyme (ACE), the angiotensin type 1 receptor (AT1R), the aspartyl protease renin, and the mineralocorticoid receptor, adrenergic receptors of the sympathetic nervous system, various renal sodium transporters, and vascular calcium channels. Adequate control of blood pressure in hypertensive patients typically requires multiple treatment regimens; however, it is also estimated that blood pressure is well controlled in less than 50% of those patients with hypertension, which may reflect, in part, the influence of co-existing cardiovascular risk factors including obesity, atherosclerosis, and insulin resistance, as well as the multiple systems that contribute to the mosaic of hypertension [1,2]. In lieu of the efficacy of current antihypertensive treatments, there is extensive interest in the role of the gut microbiome on the development of hypertension and other cardiovascular disorders. Certainly, the recognition that the microbiome constitutes a far greater extent of cellular and genetic material than that of our own cells and that the biome serves a key role in maintaining nutritional and immune homeostasis underlies the current focus. Indeed, evidence to date suggests that alterations in the gut microbiota (dysbiosis) are associated with hypertension in patients and in several preclinical models [1–5]. Moreover, fecal material transfer (FMT) from hypertensive patients including preeclamptic women is associated with an increase in blood pressure and inflammation in germ-free murine recipients suggesting a mechanistic role of the gut biome [6,7]. In this regard, Raizada and colleagues propose that gut dysbiosis is a causative factor in the development of hypertension that may arise from enhanced sympathetic tone, reduced mesenteric blood flow, and an increased systemic inflammation [8]. This stimulated inflammatory system may reflect alterations in the junction of epithelial cells (leaky gut) that lead to increased permeability of the endotoxin lipopolysaccharide (LPS), a membrane component of Gram-negative bacteria that constitute the majority of gut bacteria, as well as other pathogen-associated molecular patterns (PAMPs) that stimulate toll-like receptors, such as TLR-2 and TLR-4 [2–4]. The overall balance of the gut microbiota composition may also influence the regulation of blood pressure. Reduced abundance of Lactobacillus species is associated with hypertension and may reflect a deficit in the generation of Lactobacillus-derived peptides that exhibit ACE inhibitory activity [5]. Attenuated ACE activity would not only reduce Ang II levels and activation of the AT1R axis but also promote greater expression of the vasodilatory and anti-inflammatory peptide Ang-(1–7). Oral administration of Ang-(1–7) expressed in the probiotic Lactobacillus paracasei markedly increased the circulating levels of the peptide that was associated with improved indices of microbiome diversity in aged Fisher 344 rats, particularly an increase in the anti-inflammatory species Akkermansia muciniphila, also linked to the integrity of the gut barrier [9]. Additionally, certain microbiota species generate short-chain fatty acids (SCFAs) including propionate, succinate, and butyrate [2–4]. The production of butyrate may be protective to the cardiovascular system as this SCFA exhibits anti-inflammatory properties that may reflect the inhibition of histone deacetylase (HDAC) activity [4]. SCFAs may also have beneficial effects by stimulating specific fatty acid receptors (FFAR) that have direct vasodilatory effects or may stimulate FFARs on vagal afferents in the gut to elicit parasympathetic pathways in the brain to lower pressure that may be the basis for a microbiome gut--brain axis to regulate blood pressure [3,8]. Indeed, in a clinical study of overweight and obese pregnant women, blood pressure was inversely associated with butyrate-producing gut microbiota populations giving further evidence suggesting the antihypertensive role of bacterial generated SCFA [10]. A key issue regarding the role of the microbiome in hypertension and other cardiovascular disorders is whether gut dysbiosis is a causative insult leading to a sustained increase in blood pressure or that hypertension impacts the microbiome to an extent that the altered microbiota contributes to the progression and/or continued hypertensive state. Konopelski et al.[11] address this issue in a crossed FMT study between an experimental model of primary hypertension in the spontaneously hypertensive rat (SHR) and the Wistar Kyoto (WKY) rat as the normotensive control group. The underlying mechanism(s) for the increase in blood pressure in this genetic model of hypertension remains undefined, and the SHR is considered a relevant model of human primary hypertension. This study performed colonic transplant of fecal material from male SHR or WKY into each recipient group (SHR FMT to WKYSHR; WKY FMT to SHRWKY) pretreated with the broad-spectrum antibiotic neomycin to clear the host biome and blood pressure was continuously monitored by telemetry [11]. Controls included both WKY and SHR groups that received corresponding FMT (WKY to WKYWKY and SHR to SHRSHR) to account for all surgical procedures. Fecal material was obtained from 14-week-old donor rats and colonic transplants performed in 9-week-old recipients. In the SHR at 9 weeks of age, blood pressure continues to increase but pressure is well established and plateaus by 14 weeks of age. Apart from differences in
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1097/hjh.0000000000002908
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Cook, K.L., & Chappell, M.C. (2021). Gut dysbiosis and hypertension: is it cause or effect?. <em>Journal of Hypertension</em>. https://doi.org/10.1097/hjh.0000000000002908
Vancouver
Cook KL, Chappell MC. Gut dysbiosis and hypertension: is it cause or effect?. Journal of Hypertension. 2021. doi:10.1097/hjh.0000000000002908.
BibTeX
@unpublished{katherine2021Gutdys,
title = {Gut dysbiosis and hypertension: is it cause or effect?},
author = {Katherine Loree Cook and Mark C. Chappell},
journal = {Journal of Hypertension},
year = {2021},
doi = {10.1097/hjh.0000000000002908},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Kerala Journal of Ophthalmology 2026
Open access · CC-BY
Gut microbiome and uveitis: Evaluating the gut-eye axis hypothesis
Milton S. Hershey Medical Center 2022
Open access · US-GOV
Angiotensin-(1-7) Cardiovascular Effects in Aging
Annals of Medicine and Surgery 2026
Open access · CC-BY
Gut microbiome dysbiosis as a trigger for area postrema syndrome exacerbation in AQP4+ NMOSD with HBV co-exposure
Frontiers in Cellular and Infection Microbiology 2020
Open access · CC-BY
Gut Microbiome Reveals Specific Dysbiosis in Primary Osteoporosis
Cells 2026
Citation only
Disruption of the Muscle-Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration.
Frontiers in Oncology 2021
Open access · CC-BY